Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany

BACKGROUND: Eligibility criteria are a critical part of clinical trials, as they define the patient population under investigation. Besides certain patient characteristics, clinical trials often include biomarker testing for eligibility. However, patient-identification mostly relies on the trial sit...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:BMC Cancer
Autori principali: Huebner, Hanna, Kurbacher, Christian M., Kuesters, Geoffrey, Hartkopf, Andreas D., Lux, Michael P., Huober, Jens, Volz, Bernhard, Taran, Florin-Andrei, Overkamp, Friedrich, Tesch, Hans, Häberle, Lothar, Lüftner, Diana, Wallwiener, Markus, Müller, Volkmar, Beckmann, Matthias W., Belleville, Erik, Ruebner, Matthias, Untch, Michael, Fasching, Peter A., Janni, Wolfgang, Fehm, Tanja N., Kolberg, Hans-Christian, Wallwiener, Diethelm, Brucker, Sara Y., Schneeweiss, Andreas, Ettl, Johannes
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2020
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7656772/
https://ncbi.nlm.nih.gov/pubmed/33176725
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-07546-1
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi